

Diabetes & Obesity

RESEARCH REVIEW™

Making Education Easy

Issue 147 – 2021

In this issue:

- CGM and glycaemic control in type 2 diabetes treated with basal insulin
- SGLT-2 inhibitors vs. sulfonylureas for type 2 diabetes
- Smartphone app for weight change and metabolic outcomes in Asians with type 2 diabetes
- CV risk prediction in type 2 diabetes before and after widespread screening
- Factors that help/hinder metformin adherence and persistence in NZ
- Diet/lifestyle interventions for overweight/obese pregnant women: early childhood outcomes
- Glycaemic control across the lifespan in NZ patients with type 1 diabetes
- Dietary potato intake and type 2 diabetes/GDM risk
- Fruit/vegetable intake and BP in overweight/obese individuals
- Interrupting sitting time and postprandial metabolism in type 2 diabetes
- Strategies for overcoming therapeutic inertia in type 2 diabetes
- Ethnicity-specific obesity BMI cutoffs based on type 2 diabetes risk

Abbreviations used in this issue

AUC = area under the curve
BMI = body mass index
BP = blood pressure
CGM = continuous glucose monitoring
CV = cardiovascular
GDM = gestational diabetes mellitus
HbA_{1c} = glycosylated haemoglobin
RCT = randomised controlled trial
RR = relative risk
SGLT = sodium glucose cotransporter

Welcome to issue 147 of Diabetes and Obesity Research Review.

This month's issue begins with research investigating the use of CGM in primary-care adult patients with type 2 diabetes treated with basal insulin without prandial insulin. Local research is well represented this month, including: i) a paper published in the Lancet looking into overestimation of CV risk predicted by equations derived prior to widespread screening; ii) interviews of Māori, Pacific and non-Māori/Pacific patients seeking to determine factors associated with adherence and persistence to metformin monotherapy; and iii) a retrospective clinical record review of patients with type 1 diabetes from the Waikato region exploring differences in glycaemic control according to age, gender, rurality and ethnicity. The issue concludes with research that has defined BMI cutoffs specific to a range of different ethnicities in the population of England for defining obesity based on type 2 diabetes risk.

We hope this slightly longer issue helps to keep you abreast of the latest research in diabetes and obesity. We always appreciate your comments and feedback.

Best regards,

Professor Jeremy Krebs

jeremykreb@researchreview.co.nz

Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin

Authors: Martens T et al., for the MOBILE Study Group

Summary: Adults from primary care with type 2 diabetes treated with 1–2 long- or intermediate-acting basal insulin injections each day without prandial insulin, with or without noninsulin glucose-lowering medications, were randomised to CGM (n=116) or monitoring with a traditional blood glucose meter (n=59) in this trial; the trial completion rate was 94%. Compared with traditional blood glucose level monitoring, CGM was associated with a greater decrease in mean HbA_{1c} level at 8 months (adjusted difference, -0.4% [p=0.02]), a greater percentage of time in the target glucose level range of 70–180 mg/dL (59% vs. 43% [p<0.001]), a smaller mean percentage of time with a glucose level >250 mg/dL (11% vs. 27% [p<0.001]) and a lower mean glucose level (179 vs. 206 mg/dL [p<0.001]). Severe hypoglycaemic events occurred in 1% and 2% of the CGM and traditional blood glucose level monitoring groups, respectively.

Comment: Clinically, we all have plenty of examples of patients with type 1 diabetes who have turned their diabetes around with the use of CGM. The role for CGM in people with type 2 diabetes is much less well defined, although again for some people, it seems to be a tool that enables them to achieve better control. This may be simply due to better awareness of glucose response to food and activity, or may be related to informing insulin dosing. Increasing our understanding of which factors predict a good response will help in discussions with patients, and also potentially inform the debate about funding. This study shows that CGM compared with regular capillary monitoring helped achieve better reduction in HbA_{1c} level in people with poorly controlled type 2 diabetes on basal insulin but not using bolus insulin. Whilst statistically significant, the difference between groups was pretty small (-0.4%, or ~5 mmol/mol). As with any such group mean data, there would have been individuals within the CGM group who did much better than this, and understanding their characteristics would be very helpful.

Reference: JAMA 2021;325:2262–72

[Abstract](#)

CLICK HERE to read previous issues of Diabetes & Obesity Research Review

NEW



PATIENTS TAKING CONTRAVE ACHIEVED SIGNIFICANT AND SUSTAINED WEIGHT LOSS WHILE ON THERAPY^{1,2,7,8}

¹At 56 weeks, compared to placebo (-8.1% vs -1.8%, p<0.0001), in patients with obesity or who are overweight with one or more weight related comorbidities, in conjunction with a reduced-calorie diet and increased physical activity. ²e.g. type 2 diabetes, dyslipidaemia, controlled hypertension.

CONTRACE RESPONDER/COMPLETERS[#] ACHIEVED 11.6% WEIGHT LOSS FROM BASELINE TO 56 WEEKS.^{*9}

^{*}Post hoc pooled analysis of responders/completers[#] from Phase 3 Contrace development program. [#]Responders/completer population achieved ≥5% weight loss at week 16 and completed 56 weeks of treatment.

Prescribe Contrace in conjunction with reduced-calorie diet and increased physical activity. Please review full Data Sheet before prescribing, available by clicking [here](#)

References: 1. Contrace Data Sheet. 2. Biller SK et al. Pharmacol Res 2014;64:111–3. Australian and New Zealand Obesity Society. Australian Obesity Management Algorithm. Available at: www.anzoss.com/publications (accessed April 2021). 4. Dismore Data Sheet. 5. Savenda Data Sheet. 6. Xenical Data Sheet. 7. Greenway FL et al. Lancet 2010;376(9741):595–605. 8. Hollander P et al. Diabetes Care 2013;36(12):4022–9. 9. Fujioke K et al. Int J Obes 2016;40(13):1369–1375.

© 2021 Novartis Pharmaceuticals (Australia) Pty Limited, Level 10, 12 Help Street, Cheltenham NSW 2057, Australia. Distributed in New Zealand by Radiant Health Ltd, c/o Supply Chain Solutions, 74 Westney Road, Airport Oaks, Auckland. Toll free 0800 375 394. NZ 021 04 0002. 7475 NA 12071. April 2021.

CLICK HERE

FOR FULL MANDATORIES

For more information, please go to www.medsafe.govt.nz

www.researchreview.co.nz

a RESEARCH REVIEW™ publication




Jardiance®
(empagliflozin)

FULLY FUNDED
with Special Authority criteria*
February 1st, 2021

NEW. For your patients with type 2 diabetes[†]

THE POWER TO ACCOMPLISH MORE
Above and beyond glycaemic control^{†,2}

Click below to download your JARDIANCE resources

PRESCRIBING GUIDE **PATIENT BOOKLET**

Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors vs sulfonylureas in patients with type 2 diabetes

Authors: Xie Y et al.


Summary: The effectiveness of SGLT-2 inhibitors versus sulfonylureas and associated risks of all-cause mortality were explored in a cohort of patients with type 2 diabetes; there were 23,870 SGLT-2 inhibitor recipients and 104,423 sulfonylurea recipients included in the analyses. Compared with sulfonylurea users, SGLT-2 inhibitor users had a lower risk of death from any cause (hazard ratio 0.81 [95% CI 0.75, 0.87]; -5.15 fewer deaths per 1000 person-years), irrespective of CV disease status, estimated glomerular filtration rate and the presence of albuminuria, microalbuminuria or macroalbuminuria. Continued SGLT-2 inhibitor use was also associated with a lower mortality risk compared with continued sulfonylurea use in a per-protocol analysis (hazard ratio 0.66 [95% CI 0.60, 0.74]; -10.10 fewer deaths per 1000 person-years), with a difference also seen for SGLT-2 inhibitor with versus without metformin use (0.70 [0.50, 0.97]; -7.62 fewer deaths per 1000 person-years).

Comment: There have been many papers published on the role of SGLT-2 inhibitors, and I have reviewed many of these previously. We have excellent large RCTs showing benefit of these agents in those with or at high risk of CV disease or renal disease. I have included this trial because it is real-world data and makes a comparison between SGLT-2 inhibitors and sulfonylureas, which until very recently have been the most commonly used second-line agents in NZ. It isn't an RCT, but nonetheless adds useful data to the discussion about the place of these agents. Not only does it show superiority of SGLT-2 inhibitors, but this benefit is across the board and not limited to those with high risk or established CV or renal disease. This is very relevant to NZ where we have chosen to only fund these agents in high-risk individuals.

Reference: JAMA Intern Med; published online June 28, 2021

[Abstract](#)

Kindly Supported by




South GP CME
General Practice Conference & Medical Exhibition

19-22 AUGUST 2021
HORNCastle ARENA
CHRISTCHURCH

gpcme.co.nz

[†]38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62; p<0.001).[‡]
*JARDIANCE is a funded medicine. Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. [†]In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. [‡]The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE® (p<0.001).^{1,2}

1. JARDIANCE® Data Sheet 2019 2. Zinman B et al. N Engl J Med. 2015;373(22):2117-2128

JARDIANCE® empagliflozin 10mg, 25mg film coated tablets Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>
INDICATION: Glycaemic control: Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: *Monotherapy* - When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; *Add-on combination therapy* - With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. *Prevention of cardiovascular (CV) death:* In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, JARDIANCE® should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **DOSAGE AND ADMINISTRATION:** Recommended starting dose is 10mg once daily taken with or without food. Dose can be increased to 25mg once daily. No dose adjustment is necessary for patients based on age, patients with eGFR ≥30mL/min/1.73m² or hepatic impairment. When JARDIANCE® is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with CKD stage 4 or 5 (severely impaired renal function including patients receiving dialysis; eGFR <30mL/min/1.73m² or CrCl <30mL/min). **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; diabetic ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); discontinue when eGFR is below 30mL/min/1.73m²; assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥75 years); urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (<18 years). **INTERACTIONS:** Diuretics; insulin and SU; interference with 1,5-anhydroglucitol assay. **ADVERSE REACTIONS:** *Very common:* hypoglycaemia (when used with combination with SU or insulin). *Common:* hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus; allergic skin reactions (e.g. rash, urticaria); increased urination; thirst; serum lipids increased; volume depletion (patients aged ≥75 years). For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible, highly potent and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption through SGLT2. Through inhibition of SGLT2, excessive glucose is excreted in urine. **PRESCRIPTION MEDICINE.** JARDIANCE® is a funded medicine - Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. BOEHRINGER INGELHEIM (NZ) Ltd. Level 3, 2 Osterley Way, Manukau Auckland 2104. TAPS MR7142/PC-NZ-100168 BOE000370



Boehringer Ingelheim (NZ) Ltd.
PO Box 76216 Manukau City,
Auckland 2241. Phone 0800 802 461



Eli Lilly and Company (NZ) Ltd.
PO Box 109197 Newmarket,
Auckland 1149. Phone 0800 500 056
NZBN 9429039560643

For more information, please go to www.medsafe.govt.nz



Saxenda®
liraglutide (lys)

*I have the will to train
three times a week. But I
still need help to lose
weight and keep it off.*

MICHAEL; Age: 38 BMI: 34
Patient portrayal



Visit [SAXENDACARE.CO.NZ](https://www.saxendacare.co.nz) to learn more
Click below to download your Saxenda® resources

PRESCRIBING GUIDE

PATIENT BOOKLET

Saxenda® is an unfunded prescription medicine. Doctor's fees and pharmacy charges may apply. Please review Data Sheet before prescribing. The Data Sheet can be accessed at www.novonordisk.co.nz

SAXENDA® (liraglutide (lys) 6 mg/mL). Indication: As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of ≥ 30 kg/m² (obese) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight. **Dose/administration:** Administered subcutaneously once daily at any time, independent of meals; starting dose 0.6 mg/day; increase to 3.0 mg/day in increments of 0.6 mg per week. If escalation to the next dose is not tolerated for two consecutive weeks, consider discontinuing treatment. Daily doses higher than 3.0 mg are not recommended. Must not be administered intravenously or intramuscularly. **Contraindications:** Hypersensitivity to liraglutide or any of its excipients. **Warnings/Precautions:** Not for use in patients: with obesity secondary to endocrinological or eating disorders or to treatment with medicinal products that may cause weight gain; children (<18 years); with a history of pancreatitis, severe renal impairment including end-stage renal disease, hepatic impairment or insufficiency, inflammatory bowel disease or diabetic gastroparesis; ≥ 75 years. Must not be used as a substitute for insulin. Should not be used: with insulin; in combination with other prescription, over-the-counter or complementary medicines intended for weight loss. Use with caution in patients: 65-74 years; with thyroid disease; on other drugs that increase heart rate. Advise patients of the potential risk of dehydration in relation to gastrointestinal side effects and to take precautions to avoid fluid depletion. If pancreatitis is suspected, treatment should be discontinued and appropriate management initiated. If acute pancreatitis is confirmed, Saxenda® should not be restarted. A higher rate of cholelithiasis and cholecystitis has been observed in patients treated with Saxenda® - patients should be informed of the characteristic symptoms. Cholelithiasis and cholecystitis may lead to hospitalisation and cholecystectomy. Saxenda® should be discontinued for patients who experience a sustained increase in resting heart rate. Reducing the dose of concomitantly administered insulin secretagogues to reduce the risk of hypoglycaemia should be considered. Pregnancy Category B3. Not for use during pregnancy or breast-feeding. **Undesirable effects:** Very Common: nausea, vomiting, diarrhoea, constipation. Common: dyspepsia, abdominal pain upper, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, dry mouth, gastritis, hypoglycaemia, injection site reactions, fatigue, asthenia, dizziness, dysgeusia, cholelithiasis, insomnia, increased lipase, increased amylase. (January 2020).

Novo Nordisk Pharmaceuticals Ltd., G.S.T. 53 960 898. PO Box 51268
Pakuranga, Auckland, New Zealand. NovoCare® Customer Care Center (NZ) 0800 733 737.
www.novonordisk.co.nz. © Registered trademark of Novo Nordisk A/S. ANZ205X00065.
TAPS BG1054. Prepared: March 2021.



Effect of a smartphone app on weight change and metabolic outcomes in Asian adults with type 2 diabetes

Authors: Lim SL et al.

Summary: Adults with type 2 diabetes and a BMI of ≥ 23 kg/m² were randomly allocated to diet and physical activity advice with (n=99) or without (n=105; controls) use of a smartphone app to track bodyweight, diet, physical activity and blood glucose level data, which were communicated with dietitians. Compared with controls, at 6 months participants who used the smartphone app had achieved significantly greater reductions in mean bodyweight (-3.6 vs. -1.2kg) and mean HbA_{1c} level (-0.7% vs. -0.3% overall, and -1.8% vs. -1.0% for participants with a baseline level $\geq 8\%$), and a greater proportion had reduced their diabetes medications (23.3% vs. 5.4%). There were also between-group differences for fasting blood glucose level, diastolic BP and dietary changes favouring the smartphone app group.

Comment: Use of smartphone apps to support patient management has become very popular across a wide range of long-term conditions. With high rates of smartphone use across the population, these are potentially very powerful tools. However, the results from RCTs using apps to support management of weight or diabetes have been very mixed, and generally underwhelming compared with their potential. This study is another RCT of a phone app-based intervention to facilitate weight loss in people with type 2 diabetes in Singapore. This particular study did show modestly greater weight loss and better metabolic outcomes using a culturally customised app. Once again, we need to know what the factors are that determine which patients are most likely to use these apps to achieve better results.

Reference: *JAMA Netw Open* 2021;4:e2112417
[Abstract](#)

Cardiovascular risk prediction in type 2 diabetes before and after widespread screening

Authors: Pylypchuk R et al.

Summary: This derivation and validation study from NZ sought to determine if CV risk prediction equations derived prior to widespread screening would significantly overestimate CV risk in screen-detected patients. Patients aged 30-74 years with type 2 diabetes and no known CV disease, heart failure or substantial renal impairment (n=46,652; PREDICT-1° Diabetes subcohort) were identified from the PREDICT primary-care cohort study, which covered the periods before and after widespread screening; 31.8% were not receiving oral hypoglycaemic medications or insulin at baseline. New sex-specific equations derived from this cohort returned median 5-year CV risk estimates of 7.1% and 4.0% for men and women, respectively, compared with respective risk estimates of 17.1% and 14.2% according to an older equation derived in the 2000-2006 NZDCS (New Zealand Diabetes Cohort Study). The new PREDICT-1° Diabetes equations were significantly superior to the NZDCS equation for measures of model and discrimination performance.

Comment: This is a very important paper in the context of NZ primary care management of CV risk. For many years we have used a risk estimate of individuals derived from the Framingham study, which is historical and not derived from a NZ population. Various modifications and additions to this have been made over the years to try to build diabetes into the equations, recognising that people with diabetes may be at greater risk of CV disease than the rest of the population. This paper now describes a contemporary calculator for estimating CV disease risk in type 2 diabetes derived from real-world population data that are truly representative of the NZ population. It is clear from these data that the older calculators overestimated CV disease risk for many people with type 2 diabetes. This tool will provide a more accurate estimate of risk for guiding patient management.

Reference: *Lancet* 2021;397:2264-74
[Abstract](#)



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

For more information, please go to www.medsafe.govt.nz

What helps and hinders metformin adherence and persistence

Authors: Parkin L et al.

Summary: Face-to-face, audio-recorded, semistructured interviews were conducted with ten Māori, ten Pacific and ten non-Māori non-Pacific metformin monotherapy initiators for type 2 diabetes to determine factors influencing adherence and persistence. The reported perceived benefits of metformin included better glycaemic control, preventing or slowing type 2 diabetes progression and avoidance of serious complications, and the most frequently reported disadvantage was side effects (predominantly gastrointestinal). Interviewees reported use of a range of strategies to facilitate regular metformin use. The main reasons for initial suboptimal adherence and persistence were side effects and failing to accept their diagnosis of type 2 diabetes. Subsequent omission of missing doses was usually due to forgetfulness. Other important contributors to suboptimal adherence among Pacific people were changes in their routine due to community and church events or shift work. Some Māori interviewees indicated that they would have preferred to use traditional medicines.

Comment: Metformin is the first agent for the management of type 2 diabetes in any algorithm. However, uptake and ongoing use of metformin is not universal. This NZ study explores why that is, from a patient perspective. The main reason that emerged relates to gastrointestinal side effects, which we know are common. It is interesting that not accepting the diagnosis of diabetes was also an important finding. Forgetfulness and changes in routine are likely not specific to metformin, and may be overcome to some extent by use of blister packs or self-generated phone prompts. These are useful findings to assist in patient care.

Reference: *N Z Med J* 2021;134(1536):25–40

[Abstract](#)

Independent commentary by Professor Jeremy Krebs MBChB, FRACP, MD



Professor Krebs is an Endocrinologist with a particular interest in obesity and diabetes. He trained in Endocrinology at Wellington Hospital in New Zealand and then did his doctorate with the Medical Research Council - Human Nutrition Research unit in Cambridge England. **FOR FULL BIO [CLICK HERE](#).**

RACP MyCPD Program participants can claim one credit per hour (maximum of 60 credits per year) for reading and evaluating Research Reviews.

FOR MORE INFORMATION [CLICK HERE](#)

The effects of dietary and lifestyle interventions among pregnant women with overweight or obesity on early childhood outcomes

Authors: Louise J et al.

Summary: This was an individual participant data meta-analysis from six trials that had randomised women with a singleton, live gestation between 10+0 and 20+0 weeks and a BMI of ≥ 25 kg/m² in early pregnancy to either a diet and/or lifestyle intervention or standard antenatal care, and that reported longer-term maternal (n=2383) and child (n=2529) follow-up (3–5 years of age) outcomes. A BMI z-score in the >90th percentile was seen in ~30% of the children, with no significant difference between the intervention and control groups for this primary childhood outcome (adjusted RR 0.97 [95% CI 0.87, 1.08]) or for any of the secondary childhood outcomes assessed (skinfold thickness measurements, body circumferences, fat-free mass, diet and physical activity patterns, BP and neurodevelopment).

Comment: There are many studies showing the association between maternal obesity, GDM and childhood obesity in the offspring. There continues to be the eternal debate over how much of this is related to genetics versus environment, with studies supporting both hypotheses, and most concluding that each is important. Further to this debate is whether interventions during pregnancy might influence the intrauterine environment and modify the childhood outcome. This study reports a meta-analysis of individual participant-level data from diet and/or lifestyle intervention studies in pregnant women. Disappointingly, there is no evidence that weight management during pregnancy reduces childhood obesity.

Reference: *BMC Med* 2021;19:128

[Abstract](#)

Choose to add in Lantus® for Type 2 Diabetes patients with an HbA1c of >53mmol/mol^{1,2#}

Reasons to use Lantus®.

Lantus® once-daily in Type 2 Diabetes³:

- Has proven efficacy in reducing HbA1c³⁻⁵
- Is associated with a lower risk of hypoglycaemia compared with NPH⁶⁻⁸
- Is easy to initiate and for patients to self titrate⁹

¹After lifestyle and oral diabetes medication optimisation. The target HbA1c in most patients with diabetes is < 53 mmol/mol²

[#]Excluding severe hypoglycaemia



References: 1. Melanie J. Davies et al. *Diabetes Care* 2018; 41:2669-2701. Reference 2. Type 2 diabetes Management Guidance. NZSSD. 2021. 3. Lantus Data Sheet. 31 July 2017. 4. DeVries J H. *Eur Endocrinol* 2014;10(1):23-30. 5. Gerstein HC, et al. *N Engl J Med* 2012;367:319–28. 6. Bazzano L A, et al. *Diabetic Medicine* 2008;25:924–932. 7. Horvath K, et al. Long acting insulin analogues vs NPH insulin (Human isophane insulin) for Type 2 Diabetes Mellitus. *Cochrane Review* 2009. 8. Home P.D, et al. *Diabetes, Obesity and Metabolism*. 2010; 12:772–779. 9. Davies M et al. *Diabetes Care*. 2005; 28:1282–88.

Lantus® Abridged Data Sheet

Please review Full Data Sheet before prescribing – available at www.medsafe.govt.nz or from the sponsor.

Lantus® (insulin glargine). **Indication:** Once-daily subcutaneous administration for type 1 and type 2 diabetes mellitus patients who require insulin for control of hyperglycaemia. **Contraindications:** Hypersensitivity to insulin glargine or any excipient. **Precautions:** Hypoglycaemia, possibly with delayed recovery or altered warning symptoms; hepatic, renal and visual impairment; lipodystrophy and other injection site or immediate-type allergic reactions; antibody production; not studied in children <6 years, pregnancy category B3, lactation; not intended for i.v. use; not recommended for treatment of diabetic ketoacidosis; LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. Patient instruction on intercurrent conditions, blood glucose monitoring, injection technique recommended. **Interactions:** Oral antidiabetic agents; cardiovascular, analgesic, anti-inflammatory, neurological, antipsychotic agents, antibiotics, corticosteroids, other hormonal therapies, diuretics, protease inhibitors, sympathomimetic agents, lithium, alcohol, sympatholytics including β -blockers, others. **Adverse effects:** Hypoglycaemia; injection site reactions; visual disturbances; others. **Dosage and Administration:** Subcutaneous, once daily; abdominal, thigh or deltoid administration; blood glucose monitoring is recommended. Lantus® is equivalent to human insulin. Initial dose should be determined individually, depending on desired blood glucose levels and doses and timing of any antidiabetic medication, including Lantus®. For changeover from once-daily NPH initial dose usually not changed; for changeover from twice-daily NPH to once-daily Lantus®, initial dose usually reduced by approximately 20% compared to total daily NPH dose; for initiation of type 2 patients, initial dose is usually approximately 10IU. For secondary dose adjustments, renal, hepatic impairment see full Data Sheet. **Medicine Classification:** Prescription Medicine. **Presentations:** Lantus® (insulin glargine injection) 100 U per mL is available in packs of 5x3mL cartridges, 5x3mL cartridges in SoloStar pre-filled pens and 10mL vials. **Sponsor:** Sanofi New Zealand, Level 8, 56 Cawley Street, Ellerslie, Auckland. Free phone 0800 283 684. Lantus® is a Funded Medicine. TAPS PP7259 MAT-NZ-2100013. Date of preparation February 2021.

For more information, please go to www.medsafe.govt.nz

Glycaemic control across the lifespan in a cohort of New Zealand patients with type 1 diabetes mellitus

Authors: Chepulis L et al.

Summary: Differences in glycaemic control according to age, gender, rurality and ethnicity were explored in this retrospective review of clinical records of 1303 patients with type 1 diabetes from the Waikato region. Median HbA_{1c} level was 67 mmol/mol (8.3%), with the highest levels seen in patients aged 15–29 years and levels in excess of clinical recommendations seen in 85.3% of all participants. Compared with patients on multiple daily injections, those on insulin pumps had a lower median HbA_{1c} level (63 vs. 69 mmol/mol, or 7.9% vs. 8.5% [$p < 0.001$]), although Māori and men were significantly less likely to be insulin pump users. Glycaemic control worsened significantly as social deprivation increased, but was not significantly affected by rural versus urban living.

Comment: It is always good to have NZ data and studies to include in this review. Here is a retrospective review of glycaemic control in people with type 1 diabetes included in the diabetes register in the Waikato region. We know that control varies over time as various factors come to play for people with type 1 diabetes. Here the authors have simply taken the most recent HbA_{1c} level as representative. Despite all of the effort made by individuals with diabetes and the team helping them, it is striking that <15% were achieving target control. This highlights just how hard it is. Although those who were using an insulin pump had slightly better control, the difference is not huge and in this type of study cannot necessarily be attributed to the pump itself rather than other factors. It is notable that other determinants of health were related to control, as is seen in so many health outcomes.

Reference: *Intern Med J* 2021;51:725–31

[Abstract](#)

Independent Content: The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. **Research Review publications are intended for New Zealand health professionals.**



At all stages of your medical career, the NZMA is your voice, advocating on the issues that affect you, your colleagues and the health of all New Zealanders. A strong membership means we can do more.

Join us today.
www.nzma.org.nz
or scan the code above



Dietary potato intake and risks of type 2 diabetes and gestational diabetes mellitus

Authors: Guo F et al.

Summary: This was a meta-analysis of 19 studies reporting data on associations of potato consumption with type 2 diabetes and GDM; 13 studies reported on 21,357 cases of type 2 diabetes among 323,475 participants, and six reported on 1516 cases of GDM among 29,288 pregnancies. Significant positive associations were seen for type 2 diabetes risk with intake of any potato (RR 1.19 [95% CI 1.06, 1.34]), baked/boiled/mashed potato (1.08 [1.00, 1.16]) and French fries/fried potato (1.33 [1.03, 1.70]) among Western populations, with significant 10%, 2% and 34% increased risks of type 2 diabetes for each 80 g/day serving of any potato, unfried potato and fried potato intake, respectively (p values for trends, <0.001, 0.02 and <0.001). There were also nonsignificant increases in GDM risk for any potato and fried potato intake (respective RRs 1.19 [0.89, 1.58], and 1.03 [0.97, 1.09]) in Western countries, with significant associations seen for each 80 g/day increase in consumption (1.22 [1.06, 1.42] and 1.26 [1.07, 1.48], respectively [p values for trends, 0.007 and 0.006]).

Comment: The poor old humble potato! Potato has been a staple carbohydrate for many Western diets for centuries. Rates of type 2 diabetes have only really increased significantly over the last 30–40 years. So can we really blame the potato? This meta-analysis suggests that there is a dose-response relationship between daily potato consumption and risk of diabetes. Notably, this is driven mostly by fried potato consumption and would suggest a contribution if not interaction between fat and carbohydrate intake and/or total energy intake as the important factor. It would be interesting to see a similar analysis for other staple carbohydrates such as rice, bread or pasta, and to see this adjusted for total energy.

Reference: *Clin Nutr* 2021;40:3754–64

[Abstract](#)

Dietary interventions and blood pressure in overweight or obese individuals


Authors: Arnott K et al.

Summary: This systematic review and meta-analysis included ten RCTs ($n = 6862$) investigating the effects of interventions of increased fruit and vegetable consumption on BP in participants with a BMI of ≥ 25 kg/m². Overall, fruit and vegetable consumption interventions were associated with decreases in systolic and diastolic BP of 2.16 and 0.55 mm Hg (p values <0.001 and 0.39), respectively. Greater decreases in systolic BP were evident in participants from the community and medical schools rather than healthcare/programmes, with interventions that used the DASH diet, and when fruit and vegetable consumption was recorded in food diaries. Decreases in systolic BP were less when concealed allocation was used and fidelity checked. The greater the fruit and vegetable consumption, the greater were the decreases in systolic and diastolic BP.

Comment: Fruit and vegetable consumption has been associated with many positive health outcomes in many population studies. This meta-analysis has specifically focussed on studies that have used a fruit and vegetable intervention on BP in overweight or obese individuals. Given the extensive body of dietary intervention literature, it is surprising that there were only ten studies that met the inclusion criteria. Furthermore, the quality of the studies identified and the possibility that there is a publication bias means that it is difficult to draw confident conclusions. However, as expected it appears that there is a dose-response effect of increased fruit and vegetable intake on BP in overweight and obesity.

Reference: *Clin Nutr*; published online June 10, 2021

[Abstract](#)



CHOOSE EASY

The #1 sensor-based glucose monitoring system used worldwide with more than 3 million users globally¹

FreeStyleLibre.co.nz

FreeStyle
Libre
FLASH GLUCOSE MONITORING SYSTEM



The FreeStyle Libre Flash Glucose Monitoring System is indicated for measuring interstitial fluid glucose levels in people (aged 4 and older) with insulin-dependent diabetes. The indication for children (age 4 - 17) is limited to those who are supervised by a caregiver who is at least 18 years of age. Always read the instructions for use. The sensor must be removed prior to Magnetic Resonance Imaging (MRI). Not all CGM/Flash GM products are indicated for use in all conditions or all age groups. CGM, continuous glucose monitoring; GM, glucose monitoring. **Reference:** 1. Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use sensor-based glucose monitoring systems. FreeStyle, Libre, and related brand marks are marks of Abbott. Information contained herein is for distribution outside of the USA only. For more information call Customer Service on 0800 106 100. Med'l Ray New Zealand, 53-55 Paul Matthews Road, Albany, Auckland 0632 www.mediray.co.nz NZBN 9429041039915 ADC-41308 v1.0

life. to the fullest.
Abbott

Frequency of interruptions to sitting time: benefits for postprandial metabolism in type 2 diabetes

Authors: Homer AR et al.

Summary: Twenty-three adults with medication-controlled type 2 diabetes participated in this three-arm randomised, crossover trial with 6- to 14-day washout. The study arms consisted of sitting uninterrupted for 7 hours, sitting and 3-minute simple resistance activities (half squats, calf raises, gluteal contractions and knee raises) every 30 minutes, and sitting with 6 minutes of simple resistance activities every 60 minutes. Greatest attenuation of the respective glucose and insulin 7-hour net incremental AUCs was seen with sitting with 6 minutes of activities every 60 minutes (17.0 mmol-h/L and 1229 pmol-h/L compared with sitting only (21.4 mmol-h/L and 1411 pmol-h/L [$p < 0.05$]); the difference compared with sitting and 3-minute simple resistance activities every 30 minutes was significant only for glucose (22.1 mmol-h/L [$p = 0.01$]), and there were no significant differences for glucose or insulin net incremental AUCs for the comparison of sitting plus 3-minute activities every 30 minutes and sitting only. Triglyceride net incremental AUC was not significantly affected by any of the study conditions.

Comment: What a great little study. Prolonged sedentary time is a strong risk factor for type 2 diabetes and is a predictor of worse glycaemic control in established diabetes. So many jobs are now desk-based, and unless people very actively avoid or reduce sedentary time, people can spend many hours sitting. This small crossover study explored whether a simple brief activity intervention carried out every 30 or 60 minutes improves parameters of glucose metabolism in people with type 2 diabetes. Doing 6 minutes of simple resistance activities every 60 minutes resulted in significant improvements compared with a sitting control. This level of intervention is practical and could be implemented in the workplace. It further reinforces my adoption of a standing desk for consultations. I still can't get most patients to stand with me though!

Reference: *Diabetes Care* 2021;44:1254–63

[Abstract](#)

Endocrinologist Dr Ole Schmiadel reviews Contrave® (Naltrexone/Bupropion)

This review discusses the use of naltrexone/bupropion, a new treatment for weight management in patients with obesity or who are overweight with at least one weight-related comorbidity.



CLICK HERE

Strategies for overcoming therapeutic inertia in type 2 diabetes

Authors: Powell RE et al.

Summary: This was a systematic review with nonlinear random-effects meta-regression meta-analysis of 36 studies ($n = 22,243$) examining the effects of interventions (median duration 1 year) to overcome therapeutic inertia on HbA_{1c} level control in patients with type 2 diabetes. Compared with the control arms, changes in HbA_{1c} level ranged from: i) -17.7 to -4.4 mmol/mol, or -1.62% to -0.40% , for nurse- or certified diabetes educator-based interventions; ii) -13.1 to $+3.3$ mmol/mol, or -1.20% to $+0.30\%$, for care management and patient education interventions; iii) -9.8 to -6.6 mmol/mol, or -0.90% to -0.60% , for pharmacist-based interventions; and iv) -4.4 to $+2.8$ mmol/mol, or -0.40% to $+0.26\%$, for physician-based interventions. HbA_{1c} levels only declined significantly during the first year in participants with preintervention HbA_{1c} levels of >75 mmol/mol, or $<9\%$, across all studies (-4.2 and -1.6 mmol/mol, or -0.38% and -0.15% , at 6 months and 1 year, respectively).

Comment: There is good evidence that therapeutic inertia is a common problem in the management of type 2 diabetes. Previous studies have identified both patient and practitioner factors in this inertia. This study systematically reviewed the literature of interventions designed to reduce clinical inertia. The results focus on the impact of different members of the multidisciplinary team leading the intervention. It doesn't surprise me at all that the outcomes for improved glycaemic control were better when led by nonphysician providers – nurses and pharmacists. Management of diabetes is an ideal example of where the whole of the team have very important roles and the best outcomes are achieved when the team functions as a team with a common goal and common messages. This paper supports the growing structure in primary care of prescribing nurses and pharmacists in long-term condition management.

Reference: *Diabetes Obes Metab*; published online June 27, 2021

[Abstract](#)

Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England

Authors: Caleyachetty R et al.

Summary: Ethnicity-specific BMI cutoffs for obesity were determined according to type 2 diabetes risk for a population-based cohort of 1,472,819 individuals in England, of whom 90.6% were White, 5.2% were south Asian, 3.4% were Black, 0.7% were Chinese and 0.2% were Arab. Type 2 diabetes was diagnosed in 6.6% of the cohort over median follow-up of 6.5 years. For the equivalent age-adjusted and sex-adjusted incidence of type 2 diabetes at a BMI of 30.0 kg/m² among the White individuals, the respective BMI cutoffs for the south Asian, Black, Chinese and Arab populations were 23.9, 28.1, 26.9 and 26.6 kg/m².

Comment: BMI is a surrogate measure of body fatness. The cutoffs we usually use for overweight and obesity are derived from Caucasian populations and relate to risk of developing CV disease. Body composition varies by ethnicity, with differences in the ratio of fat to lean body mass. Therefore, it is to be expected that the standard BMI formula might not be able to be translated to non-Caucasian ethnicities as an estimate of fat mass or the cutoffs be appropriate for identifying risk for CV or metabolic disease. This excellent study from the UK used longitudinal primary-care data to identify BMI cutoffs across different ethnicities that predict risk of type 2 diabetes compared with a cutoff of 30 kg/m² for Caucasians. As expected for ethnicities who have a higher incidence of type 2 diabetes, the BMI cutoff is lower. What surprised me was just how low it is for south Asian populations at 23.9 kg/m², which is within the healthy range for Caucasians. In NZ, we really need to know how this analysis looks for Māori and Pacific populations. The data we do have would suggest that although BMI cutoffs for estimation of fat mass are higher than Caucasians, the metabolic risk is similar at the Caucasian cutoff, and therefore shouldn't be adjusted.

Reference: *Lancet Diabetes Endocrinol* 2021;9:419–26

[Abstract](#)



SPECIAL REPORT: NZSSD Type 2 Diabetes Management Guidelines 2021

This Special Report by Dr Ryan Paul, who was the lead on the guidelines working party, provides a summary of and commentary on the Type 2 Diabetes Management Guidance for the busy health care worker.

CLICK HERE to read the PDF online

